AI assistant
Sending…
BridgeBio Pharma, Inc. — Director's Dealing 2024
Feb 13, 2024
30604_dirs_2024-02-13_b6dca220-b362-44b4-a5b4-6c0c5293da9a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-28
Reporting Person: Valantine Hannah (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-28 | Common Stock | P | 1891 | $13.18 | Acquired | 1891 | Indirect |
| 2021-12-28 | Common Stock | P | 1542 | $12.68 | Acquired | 3433 | Indirect |
More from BridgeBio Pharma, Inc.
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 20
Director's Dealing
2026
Mar 3